Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 or older,~* signed informed concern,~* within 2 hours of ICU admission,~* diagnosed alcohol withdrawal syndrome or alcohol withdrawal delirium by DSM IV criteria~Exclusion Criteria:~* younger than 18 or older than 75,~* history of use or withdrawal states of other psychoactive substances,~* general anesthesia during last 24 hours or known other sedatives use,~* severe neurologic disorder (traumatic brain injury, acute stroke, severe dementia),~* pregnancy or lactation,~* severe comorbidities (severe heart failure, acute myocardial infarction, heart rate \<50/min, glomerular filtration rate \< 30 ml/min, liver failure Child-Pugh class C),~* known allergy to the study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group D (Type: EXPERIMENTAL): Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
- Group C (Type: NO_INTERVENTION): Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).